Cell Robotics Completes Private Placement
ALBUQUERQUE, N.M., Feb. 28 -- Cell Robotics International has announced the completion of a non-brokered, $1.08-million private placement involving 450,000 shares of the company's common stock. The transaction also included an option to purchase an additional 50,000 shares of common stock under the same terms during the next eight weeks. In addition, the investor is to be appointed to the current board of directors and to be nominated to the board of directors for vote by the shareholders at the company's annual meeting in May 2000. Cell Robotics described the investor as an experienced international technologist and manager who is the president of his own engineering company.
The company plans to use the proceeds from this private placement primarily for the manufacturing, sales and marketing efforts of its proprietary laser device, the Personal Lasette. Cell Robotics said the Personal Lasette is the only FDA-cleared alternative to the needle or steel blade lancet currently available for diabetics to use in drawing blood to test their glucose levels.
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024